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Abstract 
 
UDP-Glucuronosyltransferase (UGT) 2A3 belongs to a UGT superfamily of phase II drug-
metabolizing enzymes that catalyzes the glucuronidation of many endobiotics and xenobiotics. 
Previous studies have demonstrated that UGT2A3 is expressed in the human liver, small 
intestine, and kidney at the mRNA level; however, its protein expression has not been 
determined. Evaluation of the protein expression of UGT2A3 would be useful to determine its 
role at the tissue level. In this study, we prepared a specific antibody against human UGT2A3 
and evaluated the relative expression of UGT2A3 in the human liver, small intestine, and 
kidney. Western blot analysis indicated that this antibody is specific to UGT2A3 because it 
did not cross-react with other human UGT isoforms or rodent UGTs. UGT2A3 expression in 
the human small intestine was higher than that in the liver and kidney. Via treatment with 
endoglycosidase, it was clearly demonstrated that UGT2A3 was N-glycosylated. UGT2A3 
protein levels were significantly	correlated with UGT2A3 mRNA levels in a panel of 28 
human liver samples (r = 0.64, p < 0.001). In conclusion, we successfully prepared a specific 
antibody against UGT2A3. This antibody would be useful to evaluate the physiological, 
pharmacological, and toxicological roles of UGT2A3 in human tissues.  
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glucuronic acid; UGT, UDP-glucuronosyltransferase; UTR, untranslated region 
 
 4 
Introduction	 	 
       UDP-Glucuronosyltransferases (UGTs) are the major phase II drug-metabolizing 
enzymes that catalyze glucuronidation of a wide variety of endogenous	and exogenous 
lipophilic substances, including steroid hormones, dietary chemicals, drugs, carcinogens, and 
other various environmental chemicals [1-3]. Glucuronidation is a step to increase the water-
solubility of these compounds and facilitate their excretion into bile or urine. In humans, 
approximately 40-70% of clinically used drugs are subjected to glucuronidation [4].  
       Human UGTs are classified into two distinct gene families, UGT1 and UGT2, which are 
subdivided into the UGT1A (1A1, 1A3, 1A4, 1A5, 1A6, 1A7, 1A8, 1A9, and 1A10), UGT2A 
(2A1, 2A2, and 2A3), and UGT2B (2B4, 2B7, 2B10, 2B11, 2B15, 2B17, and 2B28) 
subfamilies on the basis of gene structure and amino acid sequence homology [5, 6]. The 
UGT1A gene, located on chromosome 2q37, encodes nine functional enzymes by alternative 
splicing of unique exon 1 to the common exons 2-5 by exon sharing [7]. The UGT2A and 2B 
genes, located on chromosome 4q13, encode three and seven functional enzymes, 
respectively [6]. UGT2A1 and 2A2 are encoded by alternative splicing of the unique exon 1 
to the common exons 2-6, likely UGT1A family members. Moreover, UGT2A3 and 2B 
isoforms are each produced from a unique gene [6]. The UGT1A and 2B subfamilies have 
been extensively studied and functionally characterized, while little has been reported on the 
expression and function of the three members of the UGT2A subfamily.  
UGT2A3 was originally identified through screening of a guinea pig (Cavia porcellus) 
liver cDNA library [8]. UGT2A3 cDNA was subsequently cloned from the human liver, and 
then employed to prepare recombinant protein [9]. The expression of UGT2A3 mRNA has 
been detected in the human liver, small intestine, colon, adipose tissue, kidney, trachea, larynx, 
tonsil, lung, and nasal tissues [9-11]. In contrast, thus far detection of UGT2A3 protein has 
not previously been reported in any human tissue.	The lack of a specific antibody against 
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UGT2A3 is one of the reasons that it has not been analyzed. As poor correlations between the 
mRNA and protein levels were previously observed for some UGT isoforms [12, 13], the 
determination of protein levels would be necessary for the functional analysis.  In recent 
studies, liquid chromatography tandem-mass spectrometry (LC-MS/MS) analysis has been 
employed to quantify the absolute abundances of target proteins. However, this analysis is not 
widely used to date because highly sensitive and expensive LC-MS/MS instruments as well as 
highly trained and skilled staff are required. In contrast, Western blot analysis is widely used 
due to its convenience and low running cost. For such an analysis, antibodies that selectively 
react with the target protein are required. In the present study, we sought to prepare a 
monoclonal antibody that specifically recognizes human UGT2A3. Using the prepared 
antibody, we evaluated the tissue localization and interindividual variability in UGT2A3 
protein expression in human tissues. 
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Materials and Methods 
Materials 
Recombinant human UGT1As (1A1, 1A3, 1A4, 1A6, 1A7, 1A8, 1A9, and 1A10), human 
UGT2Bs (2B4, 2B7, 2B10, 2B15, and 2B17) expressed in baculovirus-infected insect cells 
(Supersomes), pooled human liver microsomes (50-donors), and pooled human small 
intestinal microsomes (7-donors) were purchased from Corning (Corning, NY). Pooled 
human kidney microsomes (6-donors) were purchased from Tissue Transformation 
Technologies (Edison, NJ). Pooled mouse or rat liver microsomes (8-week-old C57BL/6 mice 
or 7-week-old Sprague-Dawley rats, n = 3 for each sex) were prepared as previously 
described [14]. Human liver samples from 28 donors were supplied by the National Disease 
Research Interchange (Philadelphia, PA) through the Human and Animal Bridging Research 
Organization (Chiba, Japan). The information of the donors is shown in Supplemental Table. 
Microsomes were prepared as previously described [14]. The use of the human livers was 
approved by the ethics committees of Kanazawa University (Kanazawa, Japan). 
Endoglycosidase H (Endo H), peptide:N-glycosidase F (PNGaseF) and O-glycosidase were 
purchased from New England Biolabs (Ipswich, MA, USA). Restriction endonucleases and 
DNA-modifying enzymes were obtained from Takara (Shiga, Japan). All reagents were of the 
highest grade that was commercially available.	 
 
Preparation of monoclonal antibody against human UGT2A3 
The selection of the antigenic peptide, peptide synthesis, and keyhole limpet hemocyanin 
conjugation was performed by Biogate (Gifu, Japan). The antigenic peptide sequence was 
designed as follows. Hydrophilicity was evaluated by the method of Hopp and Woods [15]. 
Secondary structure was evaluated by the methods of Chou and Fasman [16] and Garnier et al. 
[17] using GENETYX-MAC software (Software Development, Tokyo, Japan). Surface 
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probability was evaluated by the method of Emini et al. [18]. Antigenicity was evaluated by 
the methods of Welling et al. [19] and Parker et al. [20] using original software. The designed 
peptide sequence was subjected to BLASTP search (http://www.ncbi.nlm.nih.gov/blast/) to 
screen its homology with known protein sequences. Based on these evaluations, the sequence 
HMPQDRTEENEIFVDLALNVLPGLSTWQS, which corresponds to residues 78 to 106 of 
human UGT2A3, was identified as a candidate peptide. At the N terminus of the synthesized 
peptide, a cysteine residue was added to facilitate conjugation to the carrier protein, keyhole 
limpet hemocyanin. A mouse monoclonal antibody against the peptide was prepared by CLEA 
Japan (Tokyo, Japan) using a standard protocol. The reactivity and specificity of hybridomas 
producing the antibodies were evaluated by Western blot analysis using a recombinant human 
UGT2A3 protein subsequently described. A clone that specifically reacted with UGT2A3 was 
expanded by intraperitoneal injection into mineral oil-primed mice. Monoclonal antibodies 
from mouse ascitic fluids were partially purified by precipitation with 33% ammonium sulfate. 
 
Cell culture 
Human hepatocellular carcinoma HepG2 or Huh-7 cells and human epithelial colorectal 
adenocarcinoma Caco-2 or LS180 cells were maintained in Dulbecco's modified Eagle's 
medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 100 
units/mL penicillin and 100 µg/mL streptomycin in an atmosphere of 5% CO2 at 37 °C. 
 
Recombinant UGT2As expressed in baculovirus-infected Sf9 cells  
Recombinant human UGT2A1, UGT2A2 and UGT2A3 were constructed using a Bac-to-
Bac Baculovirus Expression System (Invitrogen) according to the manufacturer's instructions. 
pFastBac vectors that contained human UGT2A1, UGT2A2 or UGT2A3 coding sequences 
tagged with a polyhistidine sequence at the C-terminus were previously constructed [9]. Each 
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vector was transformed into DH10Bac-competent cells, followed by transposition of the 
inserts into bacmid DNA. Spodoptera frugiperda Sf9 cells were grown in Sf-900 II SFM that 
contained 10% fetal bovine serum at 27°C without CO2. The recombinant bacmid DNA was 
transfected into Sf9 cells with Cellfectin Reagent (Invitrogen), and the virus was harvested by 
collecting the cell culture medium at 72 h post transfection. The cells were washed with ice-
cold PBS and suspended in TGE buffer [10 mM Tris-HCl (pH 7.4), 20% glycerol, and 1 mM 
EDTA], then subjected to repeated freeze-thaw cycles. The suspensions were homogenized 
with a microhomogenizer. The expression of UGT2A proteins was confirmed by Western blot 
analysis using anti-His tag antibody (data not shown). 	
 
Recombinant UGT2A3 expressed in Huh-7 cells 
 The full-length human UGT2A3 cDNA was amplified using a primer pair, 5′- 
AGAGTCGGATCCATGAGGTCTGACAAGTCAGCTT -3′ and 5′- 
CGTGTCCTCGAGCTATTCCCTCTTTTCTATCTTT -3′, and pFastBac/ UGT2A3 was used 
as a template. The amplicon was subcloned into the BamH I/Xho I sites of 
pcDNA3.1/Hygro(+) (Thermo Fisher Scientific, MA, USA). The constructed 
pcDNA3.1/Hygro(+)/hUGT2A3 plasmid was transfected into Huh-7 cells using 
Lipofectamine 2000 (Invitrogen). After 48 h, total cell homogenates were prepared by a 
previously described method [21]. Briefly, the cells were suspended in Tris-buffered saline 
[25 mM Tris-HCl buffer (pH 7.4), 138 mM NaCl, and 2.7 mM KCl] and disrupted by freeze-
thaw cycles. The suspensions were homogenized with a microhomogenizer. The protein 
concentrations of the homogenates were determined according to Bradford [22]. 
 
Preparation of microsomes from cultured cells 
Cells were scraped, pelleted and resuspended in ice-cold homogenization buffer [0.1 M 
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Tris-HCl (pH 7.4), 0.1 M KCl, and 1 mM EDTA]. The suspension was homogenized using a 
1.5 mL tube size disposable homogenizer, followed by centrifugation at 9,000 g for 15 min at 
4 °C. The supernatant was centrifuged at 105,000 g for 60 min at 4°C. The pellet was 
resuspended in ice-cold TGE buffer and sonicated. The prepared microsomes were stored 
frozen at -80 °C until use. 
 
SDS-PAGE and Western blot analysis  
Proteins were separated on a 10% SDS-PAGE and transferred onto Protran nitrocellulose 
membranes (Whatman GmbH, Dassel, Germany). These membranes were blocked with 
Odyssey blocking buffer (LI-COR Biosciences, Lincoln, NE), incubated with anti-human 
UGT2A3 monoclonal antibody, washed with PBS-T (3.2 mM Na2HPO4, 0.5 mM KH2PO4, 
1.3 mM KCl, 135 mM NaCl, 0.05% Tween20, pH 7.4), and then incubated with IRDye 680LT 
Goat anti-mouse IgG secondary antibody. The bands were visualized and their densities were 
quantified with an Odyssey Infrared Imaging system (LI-COR Biosciences) within the range 
showing linearity of the band density. UGT2A3 protein levels are expressed as the levels 
relative to that of the lowest sample, after the normalization with a control sample. The data 
are represented as the means ± SD of three independent determinations. 
 
Treatment of UGT2A3 protein with Endo H, PNGase F or O-glycosidase 
Human liver or intestinal microsomes and recombinant UGT2A3 expressed in Sf9 cells or 
Huh-7 cells were adjusted to a 2 mg/mL protein concentration with a denaturing buffer in a 
final concentration of 0.5% SDS and 40 mM DTT and were denatured at 100°C for 10 min. 
The denatured proteins (20 µg) were incubated with 250 U of Endo H in 50 mM sodium 
acetate buffer (pH 6.0), 500 U of PNGase F in 50 mM sodium phosphate buffer (pH 7.5) with 
0.1% NP-40 or 40,000 U of O-glycosidase in 50 mM sodium phosphate buffer (pH 6.0) with 
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0.1% NP-40 in a final volume of 20 µL at 37°C for 1 h; the samples were then subjected to 
SDS-PAGE and Western blot analysis. 
 
qRT-PCR  
Total RNA was extracted using RNAiso Plus (Takara) to synthesize cDNA with ReverTra 
Ace (Toyobo, Osaka, Japan). Real-time RT-PCR was performed using the Mx3000P 
(Stratagene, La Jolla, CA) with the MxPro QPCR software. The following PCR primers were 
used with the SYBR Premix Ex Taq solution (Takara): 5’-ATGAGGTCTGACAAGTC 
AGCTT-3’ and 5’-TCAAAATCCCAATATGTTCG-3’ for human UGT2A3 and 5’-
CCAGGGCTGCTTTTAACTC-3’ and 5’- GCTCCCCCCTGCAAATGA-3’ for human 
GAPDH. The PCR conditions were as follows: after an initial denaturation at 95°C for 60 s, 
amplification was performed by denaturation at 94°C for 5 s followed by annealing/extension 
at 64°C for 30 s for 40 cycles. The UGT2A3 mRNA levels were normalized to the GAPDH 
mRNA levels. UGT2A3 mRNA levels are expressed as the levels relative to that of the lowest 
sample. The data are represented as the means ± SD of triplicate determinations. 
 
Statistical analyses   
The relationship between UGT2A3 mRNA and protein was investigated using the 
Spearman's product-moment correlation coefficient. Statistical analyses were performed using 
GraphPad Prism5 at a significance level of p < 0.05. 
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Results  
 
Specificity of the human UGT2A3 antibody  
Human UGTs within the same family show high amino acid sequence homology (as high 
as 94% for some isoforms). The amino acid sequence of UGT2A3 is most similar to that of 
UGT2A2 (62% amino acid sequence identity) (Table 1). It can be emphasized that the identity 
of residues 78 to 106 of human UGT2A3, which was used as an antigen to produce the 
monoclonal antibody, with other UGTs was 34% at most (Table 1). To investigate the 
specificity of the prepared antibody, we performed Western blot analysis using human 
recombinant UGT1A, UGT2B and UGT2A proteins expressed in baculovirus-infected insect 
cells. As shown in Fig. 1A, this antibody only reacted with UGT2A3 protein.  
	
Evaluation of UGT2A3 protein expression in human and rodent tissues 
When microsomes from the human liver, kidney and small intestine were subjected to 
Western blot analysis using the new antibody against UGT2A3, a band was detected at a little 
more higher にすべきだったか than 50 kDa in all these microsomes (Fig. 1B). Following 
cleavage of the signal peptide, the predicted molecular weight of human UGT2A3 protein is 
57.7 kDa. The faster migration than theoretical molecular weight might be due to high 
binding of SDS to UGT2A3 protein, because it has been reported that hydrophobic proteins 
such as transmembrane proteins bind higher amounts of SDS than hydrophilic ones, and 
therefore they migrate faster in SDS-PAGE [23].  
The UGT2A3 protein level was highest in the intestine, followed by the kidney and then 
the liver (Fig. 1B). The UGT2A3 protein level in the liver was only about 15% the intestine 
expression level (Supplemental Figure). UGTs are known to be localized in the endoplasmic 
reticulum (ER) membrane. In accordance with this localization UGT2A3 was detected in the 
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microsomal fraction, but not in the cytosolic fraction (Fig. 1C).  
The amino acid sequence homology of the antigen peptide with rodent UGT2A3 was 
31% at most (Table 2). When the liver and intestine microsomes from mice and rats were 
subjected to Western blot analyses, no bands were detected (Fig. 1D), indicating that the 
prepared antibody did not cross-react with rodent UGTs. Thus, this antibody is highly specific 
to the human UGT2A3.  
	
UGT2A3 protein expression in human cell lines 
The expression levels of UGT2A3 protein in human hepatocellular carcinoma-derived 
cells (Huh-7 cells and HepG2 cells) and epithelial colorectal adenocarcinoma-derived cells 
(LS180 cells and Caco-2 cells) were examined. The highest UGT2A3 expression was 
observed in LS180 cells, followed by Caco-2 cells (Fig. 1E). The expression levels in Huh-7 
cells and HepG2 cells were substantially lower than those of the two colorectal cell lines. 
These results suggested that UGT2A3 is preferentially expressed in cell lines derived from the 
intestine rather than those derived from the liver.  
 
N-Glycosylation of human UGT2A3 protein	   
The glycosylation status of UGT2A3 remains unknown. A search of asparagine-linked 
(N-linked) glycosylation sites using a computational prediction tool, NetNGlyc 1.0 
(http://www.cbs.dtu.dk/services/NetNGlyc/), revealed potential N-glycosylation sites at Asn-
131 and Asn-313 in UGT2A3. A search for O-linked glycosylation sites, using the prediction 
tool NetOGlyc 4.0 (http://www.cbs.dtu.dk/services/NetOGlyc/), predicted potential O-
glycosylation sites at Thr-197 and Thr-200 (Fig. 2A). To examine whether UGT2A3 is indeed 
glycosylated, human liver microsomes (HLM), human intestine microsomes (HIM) and 
recombinant UGT2A3 in Sf9 cells were treated with the following endoglycosidases: a. Endo 
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H, which digests N-linked high-mannose carbohydrate side chains of glycoproteins; b. 
PNGase F, which catalyzes the cleavage of all N-linked oligosaccharides; c. O-glycosidase, 
which cleaves serine- or threonine-linked oligosaccharides. Cell lysates were then subjected 
to SDS-PAGE and Western blot analysis. Following the treatment with either Endo H or 
PNGase F	of HLM and HIM, a single band of UGT2A3 at 50 kDa was clearly shifted to a 
band that indicated faster mobility in SDS-PAGE. Recombinant 2A3 showed bands with 
larger molecular weight than endogenous UGT2A3, which could be attributable to the 
addition of the histidine tag and/or difference(s) in the glycosylation between insect cells and 
mammalian cells. Following treatments of the recombinant UGT2A3 with either Endo H or 
PNGase F, a new band with faster mobility appeared (Fig. 2B, upper and middle right panels). 
UGT2A3 transiently expressed in Huh-7 cells that showed the same mobility as endogenous 
UGT2A3 in HLM was also shifted by the treatment with PNGase F (Fig. 2B, middle right 
panel). These results suggest that UGT2A3 is N-glycosylated. In contrast, treatment with O-
glycosidase did not change the mobility of UGT2A3 protein in HLM, HIM or Sf9 cells (Fig. 
2B, lower panel). These results indicated that UGT2A3 undergoes post-translational N-
glycosylation. Thus, the prepared antibody might be useful for examining the function of 
UGT2A3 N-glycosylation. 
 
Interindividual variability of the UGT2A3 expression levels in the human liver  
We subsequently evaluated the relative expression levels of UGT2A3 protein and mRNA 
in a panel of 28 human livers by Western blot analysis and qRT-PCR. The variabilities in 
UGT2A3 protein and mRNA were 3-fold and 26-fold, respectively (Fig. 3A and 3B), 
indicating higher variability in the mRNA level than in the protein level. As shown in Fig. 3C, 
the UGT2A3 protein levels were significantly correlated with the UGT2A3 mRNA levels (r = 
0.64, p < 0.001).  
 14 
Discussion  
 
UGT2A3 is a relatively novel human UGT isoform, which was identified a decade ago [9]. 
Moreover, UGT2A3 is the only member of the UGT2A subfamily that was reported to 
express, at the mRNA level, in main drug metabolism tissues, namely liver, kidney and 
particularly the small intestine. By screening 81 structurally diverse glucuronidation 
substrates, it has been demonstrated that recombinant UGT2A3 expressed in baculovirus-
infected insect cells catalyzed the glucuronidation of bile acids, although its activity was 
rather low [9]. UGT2A3 mRNA is expressed in the human liver, small intestine, colon, 
adipose tissue, trachea, larynx, and tonsil [9, 11] and is expressed at low levels in the lung and 
nasal tissues [10]. However, no papers have critically assessed UGT2A3 protein expression. 
In the present study, we prepared a specific antibody against human UGT2A3 and evaluated 
the UGT2A3 protein expression in the human liver, intestine, and kidney.  
Preparation of specific antibodies against individual UGTs is not an easy objective since 
these membrane proteins shares a high degree of amino acid sequence similarity within the 
family [24]. Considering the issues, we chose a peptide sequence comprising residues 78 to 
106 of human UGT2A3, which is free from the predicted N-glycosylation sites, as an antigen 
to prepare the antibody. Using Western blot analyses with the prepared antibody and 
recombinant enzymes for each UGT isoform, it was confirmed that the antibody only 
specifically reacted with UGT2A3. Therefore, we succeeded in the preparation of a specific 
antibody against UGT2A3 (Fig. 1A). 
Substantial UGT2A3 protein expression was detected in the intestine and kidney rather 
than in the liver (Fig. 1B). This finding implicates a potential role for UGT2A3 in controlling 
the pharmacokinetics and biological effects of ingested compounds or xenobiotics. In addition, 
a recent study has suggested, via next-generation sequencing, that UGT2A3 mRNA is 
upregulated in primary colorectal cancer tissues [25]. Although it is not yet clear how this 
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mRNA increase translates into protein and whether the increased UGT2A3 expression 
accelerates carcinogenesis, that study suggested that UGT2A3 might have an endobiotic 
function in the gastrointestinal tract. Thus, confirming upregulation of the UGT2A3 protein in 
cancer tissues and elucidating its function in the development of colorectal cancer are 
interesting goals that are worth pursuing in the future. 
UGTs are membrane-bound enzymes associated with post-translational modifications 
through the ER. Some UGT isoforms are N-linked glycosylated on the ER membrane [26-30]. 
As shown in Fig. 2A, UGT2A3 also contains potential N-glycosylation sites. Using Western 
blot analysis, it was demonstrated that UGT2A3 is N-linked glycosylated (Fig. 2B). The 
mobility and band patterns of the recombinant UGT2A3 treated with Endo H and PNGase F 
were different than those of human tissues, which is due to the difference in the N-glycan 
processing pathways between mammalian and insect species [31]. The hypothesis was proven 
by the results that showed the mobility and band pattern of UGT2A3 in Huh-7 cells were the 
same as those in human liver microsomes (Fig. 2B). As previously reported for the UGT1A 
and UGT2B isoforms [29, 30], N-linked glycosylation of UGT2A3 would be important for 
appropriate protein folding and to exert enzymatic function.   
We examined the extent of interindividual variability in UGT2A3 expression in a panel 
of 28 human liver samples. The variability in UGT2A3 mRNA and protein levels was 26-fold 
and 3-fold, respectively (Figs. 3A and B). A significant positive correlation (r = 0.64, p < 
0.001) was observed between the UGT2A3 mRNA and protein levels (Fig. 3C), which 
suggests that transcriptional regulation largely contributes to the variability of the UGT2A3 
expression. In the proximal promoter region of UGT2A3, the consensus elements of several 
transcription factors, including hepatocytes, nuclear factor 1α, caudal type homeobox 2, 
pregnane X receptor, and glucocorticoid receptor, were found [9]. However, the regulation 
mechanisms of UGT2A3 have not previously been studied. In addition, functional analysis of	
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single nucleotide polymorphisms in the UGT2A3 promoter region has not been performed. It 
would be of interest to investigate whether the interindividual differences in trans- or cis-
factors for these transcription factors as well as post-transcriptional regulation are relevant to 
the variability of the UGT2A3 expression. 
In conclusion, we could successfully prepare a specific monoclonal antibody against the 
human UGT2A3. Using Western blot analyses, it was demonstrated that UGT2A3 is 
substantially expressed in the small intestine, kidney and liver, and UGT2A3 is N-linked 
glycosylated. The new antibody was useful in examining the extent of interindividual 
variability in UGT2A3 protein expression in different human tissues and its cellular 
localization. We hope that this antibody could trigger and promote structural and functional 
studies of UGT2A3 and its possible role in health and disease.  
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Figure legends 
 
Fig. 1. Western blot analysis of UGT2A3 protein using the anti-human UGT2A3 monoclonal 
antibody. (A) Recombinant UGT1A, UGT2B and UGT2A proteins expressed in baculovirus-
infected insect cells. (B) Pooled human microsomes from the liver, kidney, and intestine. (C) 
Pooled HLM or HLC. (D) Pooled liver (left panel) or intestine (right panel) microsomes from 
humans, mice and rats. (E) Microsomes from human hepatocellular carcinoma Huh-7 cells 
and HepG2 cells and human epithelial colorectal adenocarcinoma LS180 cells and Caco-2 
cells. HLM, human liver microsomes; HLC, human liver cytosol; MLM, mouse liver 
microsomes; RLM, rat liver microsomes; HKM, human kidney microsomes; HIM, human 
intestinal microsomes; MIM, mouse intestinal microsomes; RIM, rat intestinal microsomes; 
M, marker. 
  
Fig. 2. Western blot analysis of glycosylated human UGT2A3 protein. (A) Schematic 
representation of potential N- or O-glycosylation sites within the human UGT2A3 protein. (B) 
Deglycosylation of UGT2A3 protein in HLM, HIM and recombinant UGT2A3 (Sf9) with 
Endo H (upper panel), PNGase F (middle left panel), and O-glycosidase (lower panel). 
Deglycosylation of UGT2A3 protein in HLM and Huh-7 cells expressing human UGT2A3 
with PNGase F	(middle right panel). Western blot analysis was performed using the anti-
human UGT2A3 monoclonal antibody. The arrowhead and asterisk represent glycosylated 
and deglycosylated UGT2A3 protein in human liver and intestine microsomes, respectively. 
 
Fig. 3. Interindividual variability of UGT2A3 protein levels in human liver and correlation 
with UGT2A3 mRNA. (A) Expression levels of UGT2A3 protein in 28 human liver 
microsomes were determined by Western blot analysis. UGT2A3 protein levels are expressed 
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as the levels relative to that of the lowest sample, No. 16. The data are represented as the 
means ± SD of three independent determinations. (B) Expression levels of UGT2A3 mRNA 
in 28 individual human livers were determined by qRT-PCR. UGT2A3 mRNA levels were 
normalized to GAPDH mRNA levels. The values are expressed as the levels relative to that of 
the lowest sample, No. 15. The data are represented as the means ± SD of triplicate 
determinations. (C) The correlation between the UGT2A3 protein and mRNA levels in 28 
individual human livers, using the mean values in Fig. 3A and Fig. 3B.  
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Table 1         
Amino acid sequence alignment of the peptide antigen of human UGT2A3 with human UGT isoforms. 
 
Isoform Accession No. Sequence Identity with 
UGT2A3 (%) 
78-106 Full-
Length 
UGT2A3 Q6UWM9 78HMPQDRTEENEIFVDLALNVLPGLSTWQS106   
UGT1A1 P22309 80PVPFQREDVKESFVSLGHNVFENDSFLQR108 34 45 
UGT1A3 P35503 
81
AISWTQDEFDRHVLGHTQLYFETEHFLKK
109
 3 41 
UGT1A4 P22310 
81
AVPWTQKEFDRVTLGYTQGFFETEHLLKR
109
 7 42 
UGT1A6 P19224 
79
PVPYDQEELKNRYQSFGNNHFAERSFLTA
107
 17 42 
UGT1A7 Q9HAW7 
78
STSYTLEDQDREFMVFADARWTAPLRS-A
105
 7 43 
UGT1A8 Q9HAW9 
78
STSYTLEDLDREFMDFADAQWKAQVRS-L
105
 11 42 
UGT1A9 O60656 
78
STSYTLEDLDREFKAFAHAQWKAQVRS-I
105
 7 42 
UGT1A10 Q9HAW8 
78
STSYTLEDQNREFMVFAHAQWKAQAQS-I
105
 11 42 
UGT2A1 Q9Y4X1 
75
RVPFGKERIEGVIKDFVLTWLENRPSPSTIWRF
107
 17 62 
UGT2A2 Q9Y4X1-2 
84
PVSYKKSNIDSLIEHMIMLWIDHRPTPLTIWAF
116
 10 63 
UGT2B4 P06133 
78
PVSLTKTEFEDIIKQLVKRWA-EL-PKDTFWSY
108
 25 62 
UGT2B7 P16662 
78
PTSLTKTELENFIMQQIKRWS-DL-PKDTFWLY
108
 18 59 
UGT2B10 P36537 
77
PTSLTKTEFENIIMQLVKRLS-EI-QKDTFWLP
107
 18 58 
UGT2B11 O75310 
78
PTSLTKTEFENIIMQQVKRWS-DI-RKDSFWLY
108
 18 58 
UGT2B15 P54855 
78
PTSLTKNYLEDSLLKILDRWIYGV-SKNTFWSY
109
 3 60 
UGT2B17 O75795 
78
PTSLTKNDLEDFFMKMFDRWTYSI-SKNTFWSY
109
 7 61 
UGT2B28 Q9BY64 
78
PTSLTKTEFENIIMQQVKRWS-DI-QKDSFWLY
108
 18 58 
 
Multiple sequence alignment of human UGT2A3 amino acid residues 78-106 to other human UGT 
isoforms using Clustal Omega program. Identical amino acid residues from the aligned sequences are 
shown in gray boxes. 
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Table 2         
Amino acid sequence alignment of the peptide antigen of human UGT2A3 with mouse and rat 
UGT2A3  
 
Isoform Accession No. Sequence Identity with human 
UGT2A3 (%) 
78-106 Full-
Length 
Human 
UGT2A3 
Q6UWM9 78HMPQD---RTEENEIFVDLALNVLPGLSTWQS106   
Mouse 
UGT2A3 
Q8BWQ1 77PLLYEIETAENRLNEIANLAVNVIPNLSLWEA108 28 67 
Rat 
UGT2A3 
D4A147 77PVLYETEVAENHLNEIVNLAVNVIPNLSLWEA108 31 68 
 
Amino acid residues 78-106 of human UGT2A3 were aligned with the homologous sequence of 
mouse and rat using Clustal Omega program. Identical amino acid residues from the aligned 
sequences are shown in gray boxes. 
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